Key result
Baseline CMR is utilized in only ~29% of cardiomyopathy patients, varying widely by subtype.
Why the study?
CMR is recommended for diagnosing cardiomyopathies, but it is time-consuming, expensive, and limited in availability in some European regions.
What is the contemporary utilization rate and clinical determinants of cardiac magnetic resonance (CMR) imaging in the diagnosis of patients with cardiomyopathy across European tertiary referral centres?
Cohort (n=3,208)
Yes
What is the contemporary utilization rate and clinical determinants of cardiac magnetic resonance (CMR) imaging in the diagnosis of patients with cardiomyopathy across European tertiary referral centres?
Despite Class I guideline recommendations, less than one-third of patients with cardiomyopathy in European tertiary centres undergo diagnostic CMR, highlighting substantial disparities in access, training, and reimbursement across Europe.
Answers are grounded in this paper and cite their sources.
CMR underuse in cardiomyopathy signals access barriers despite guidelines; leaves open need for strategies to boost utilization and assess outcomes.
AIMS: Cardiac magnetic resonance (CMR) is recommended in the diagnosis of cardiomyopathies, but it is time-consuming, expensive, and limited in availability in some European regions. The aim of this study was to determine the use of CMR in cardiomyopathy patients enrolled into the European Society of Cardiology (ESC) cardiomyopathy registry [part of the EURObservational Research Programme (EORP)]. METHODS AND RESULTS: Three thousand, two hundred, and eight consecutive adult patients (34.6% female; median age: 53.0 ± 15 years) with cardiomyopathy were studied: 1260 with dilated (DCM), 1739 with hypertrophic (HCM), 66 with restrictive (RCM), and 143 with arrhythmogenic right ventricular cardiomyopathy (ARVC). CMR scans were performed at baseline in only 29.4% of patients. CMR utilization was variable according to cardiomyopathy subtypes: from 51.1% in ARVC to 36.4% in RCM, 33.8% in HCM, and 20.6% in DCM (P < 0.001). CMR use in tertiary referral centres located in different European countries varied from 1% to 63.2%. Patients undergoing CMR were younger, less symptomatic, less frequently had implantable cardioverter-defibrillator (ICD)/pacemaker implanted, had fewer cardiovascular risk factors and comorbidities (P < 0.001). In 28.6% of patients, CMR was used along with transthoracic echocardiography (TTE); 67.6% patients underwent TTE alone, and 0.9% only CMR. CONCLUSION: Less than one-third of patients enrolled in the registry underwent CMR and the use varied greatly between cardiomyopathy subtypes, clinical profiles of patients, and European tertiary referral centres. This gap with current guidelines needs to be considered carefully by scientific societies to promote wider availability and use of CMR in patients with cardiomyopathies.
No takes yet. Share an insight, caveat, or question.
Mizia‐Stec et al. (2020) conducted a cohort in Cardiomyopathy (dilated, hypertrophic, restrictive, or arrhythmogenic right ventricular cardiomyopathy) (n=3,208). Cardiac magnetic resonance (CMR) imaging vs. Diagnostic assessment without CMR ( primarily transthoracic echocardiography alone) was evaluated on Prevalence of baseline cardiac magnetic resonance (CMR) utilization in the diagnostic work-up of cardiomyopathy (p=<0.001). Cardiac magnetic resonance was performed at baseline in only 29.4% of cardiomyopathy patients, varying from 20.6% in DCM to 51.1% in ARVC.
Synapse has enriched 10 related papers. Consider them for comparative context: